Soligenix, Inc. (@Soligenix_Inc) header
Soligenix, Inc. (@Soligenix_Inc) profile picture

Developing life-saving products and #vaccines for inflammatory #diseases, #rarediseases and #biodefense. $SNGX

Princeton, NJ
Joined May 2012
Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)Photo by Soligenix, Inc. (@Soligenix_Inc)
Soligenix, Inc. retweeted
youtu.be/mRZ3PYPpMDk Biotech innovation continues to move forward. I recently spoke with Christopher J. Schaber, PhD, President and CEO of @Soligenix_Inc about their lead program, HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, and how they’re building a broader, diversified pipeline. With a second Phase 3 study now completed, the company is preparing for regulatory submissions and potential global commercialization. They’re also expanding into additional inflammatory and rare disease areas, supported by strategic partnerships and a multi-platform approach. It’s a compelling look at how Soligenix is positioning itself for both near-term milestones and long-term growth. #Biotech #Pharm
3
2
2
619
The Rare Disease Rubicon: Crossing The Chasm From Biotech To Bio-Commercial #defendyourhealth #SNGX talkmarkets.com/article/the-…
201
“Looking beyond science, it is execution and capital discipline that ultimately determine which biotech companies will survive” via @AsiaBioSpectrum #defendyourhealth #SNGX biospectrumasia.com/opinion/…
1
444
Early recognition for Behcet’s disease underscores how rare inflammatory conditions are becoming part of the longevity conversation. vist.ly/4vv6q @Soligenix_Inc #longevity #inflammation #raredisease #immunology #geroscience
4
7
650
NetworkNewsBreaks – $SNGX SGX945 Shows Promise with Immune-Modulating Approach nnw.fm/5qTuE
1
293
MissionIRNewsBreaks – RiVax(R) Positions $SNGX in Growing Biodefense Preparedness Efforts ibn.fm/tb4QK
3
1
1
353
$SNGX Announces Positive Phase 2 Data for Rare Inflammatory Disease nnw.fm/o46FD
1
245
MissionIRNewsBreaks – $SNGX Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM) ibn.fm/6uNh7
183
InvestorNewsBreaks – $SNGX Eyes Dermatology Market with SGX302’s Encouraging Early Results ibn.fm/jJjjp
1
360